NFKB1 and amyotrophic lateral sclerosis: These findings suggest that CTXD14SkM-EV treatment effectively suppresses NF-κB signaling in the skeletal muscles of SOD1G93A mice, supporting its potential to mitigate inflammation and muscle atrophy in ALS.